Clinical Trial

Anlotinib Capsules in the Treatment for IPF/PF-ILDs

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is an exploratory Phase 2 study evaluating the use of Anlotinib hydrochloride capsules for the treatment of IPF/PF-ILDs, with forced vital capacity (FVC) as the primary efficacy endpoint.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-06-06
critical Phase changed: Phase 2/3 -> Phase 2 2026-06-06
critical Primary endpoint(s) modified 2026-06-06
notable Primary completion pushed: 2026-03-04 -> 2026-09-30 2026-06-06
Trial Details
NCT Number NCT05828953
Lead Sponsor First Affiliated Hospital of Wenzhou Medical University
Collaborators: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Interstitial Lung Diseases
Enrollment 30 participants
Start Date 2021-09-28
Primary Completion 2026-09-30 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-05